Methoclocinnamox: Agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 934-938

  Butelman, Eduardo R ^a   Lewis, John W ^c   Woods, James H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; CLOCINNAMOX; FENTANYL CITRATE; METHOCLOCINNAMOX; MORPHINE SULFATE; MORPHINONE; MU OPIATE RECEPTOR ANTAGONIST; QUADAZOCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING KINETICS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEAT TOLERANCE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; TAIL FLICK TEST; TEMPERATURE SENSITIVITY;

ANALGESICS, OPIOID; ANIMALS; CINNAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; MACACA MULATTA; MORPHINE DERIVATIVES; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, MU;

EID: 0030441050     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. ACETO, M. D., BOWMAN, E. R., HARRIS, L. S. AND MAY, E. L.: Dependence studies of new compounds in the rhesus monkey, rat and mouse. Natl. Inst. Drug Abuse Res. Monogr. 132: 466-467, 1992.
2. ACETO, M. D., BOWMAN, E. R., MAY, E. L., HARRIS, L. S., WOODS, J. H., SMITH, C. B., MEDZIHRADSKY, F. AND JACOBSON, A. E.: Very long-acting narcotic antagonists: The 14-beto-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneim. Forsch. 39: 570-575, 1989.
3. BURKE, T., WOODS, J., LEWIS, J. AND MEDZIHRADSKY, F.: Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J. Pharmacol. Exp. Ther. 271: 715-721, 1994.
4. BUTELMAN, E. R., FRANCE, C. P. AND WOODS, J. H.: Agonist and antagonist effects of dynorphin A(1-13) in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 275: 374-380, 1995a.
5. BUTELMAN, E. R., WINGER, G., ZERNIG, G. AND WOODS, J. H.: Butorphanol: Characterization of agonist and antagonist effects in rhesus monkeys. J. Pharmacol. Exp. Ther. 272: 845-853, 1995b.
6. COMER, S. D., BURKE, T. F., LEWIS, J. W. AND WOODS, J. H.: Clocinnamox: A novel, systematically active irreversible opioid antagonist. J. Pharmacol. Exp. Ther. 262: 1051-1056, 1992.
7. COWAN, A., LEWIS, J. W. AND MACFARLANE, I. R.: Agonist and antagonist properties of buprenorphine, a new antinodceptive agent. Br. J. Pharmacol. 60: 537-545, 1977.
8. DYKSTRA, L. A., GMEREK, D. A., WINGER, G. D. AND WOODS, J. H.: Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and beta-funaltrexamine. J. Pharmacol. Exp. Ther. 242: 421-427, 1987.
9. DYKSTRA, L. A. AND NEGUS, S. S.: Behavioral and pharmacological determinants of buprenorphine's effects on schedule controlled behavior. In Buprenorphine: Combatting Drug Abuse with a Unique Opioid, ed. by A. Cowan and J. W. Lewis, pp. 49-69, Wiley, New York, 1995.
10. DYKSTRA, L. A. AND WOODS, J. H.: A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J. Pharmacol. Methods 15: 263-269, 1986.
11. GERAK, L. R., BUTELMAN, E. R., WOODS, J. H. AND FRANCE, C. P.: Antinociceptive and respiratory depressant effects of nalbuphine in rhesus monkeys. J. Pharmacol. Exp. Ther. 271: 993-999, 1994.
12. NEGOS, S. S., BUTELMAN, E. R., CHANG, K. J., DECOSTA, B. R., WINGER, G. AND WOODS, J. H.: Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J. Pharmacol. Exp. Ther. 270: 1025-1034, 1994.
13. WALKER, E. A., BUTELMAN, E. R., DECOSTA, B. R. AND WOODS, J. H.: Opioid thermal antinociception in rhesus monkeys: Receptor mechanisms and temperature dependency. J. Pharmacol. Exp. Ther. 267: 280-286, 1993.
14. WALKER, E. A., ZERNIG, G. AND WOODS, J. H.: Buprenorphine antagonism of mu opioids in the rhesus monkey tail withdrawal procedure. J. Pharmacol. Exp. Ther. 273: 1345-1352, 1995.
15. WALTER, D. S. AND INTURRISI, C. E.: Absorption, distribution, metabolism and excretion of buprenorphine in animals and humans. In Buprenorphine: Combatting Drug Abuse with a Unique Opioid, ed. by A. Cowan and J. W. Lewis, pp. 113-135, Wiley, New York, 1995.
16. WINGER, G., SKJOLDAGER, P. AND WOODS, J. H.: Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys. J. Pharmacol. Exp. Ther. 261: 311-317, 1992.
17. WOODS, J. H., LEWIS, J. W., WINGER, G., BUTELMAN, E., BROADBEAR, J. AND ZERNIG, G.: Methoclocinnamox: A μ-partial agonist with pharmacotherapeutic potential for heroin abuse. Natl. Inst. Drug Abuse Res. Monogr. 147: 195-219, 1995.
18. WOODS, J. H., SMITH, C. B., MEDZIHRADSKY, F. AND SWAIN, H. H.: Preclinical testing of new analgesic drugs. In Mechanisms of Pain and Analgesic Compounds, ed. by R. F. Beers and E. G. Bassett, pp. 429-445, Raven Press, New York, 1979.
19. ZERNIG, G., BURKE, T., LEWIS, J. W. AND WOODS, J. H.: Clocinnamox blocks only mu receptors irreversibly: Binding evidence. Regul. Pept., in press, 1996.
20. ZERNIG, G., BUTELMAN, E. R., LEWIS, J. W., WALKER, E. A. AND WOODS, J. H.: In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J. Pharmacol. Exp. Ther. 269: 57-65, 1994.